​

Beam Therapeutics Ownership | Who Owns Beam Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Beam Therapeutics Ownership Summary

Beam Therapeutics is owned by 95.85% institutional investors, 1.42% insiders, and 2.73% retail investors. Farallon capital management is the largest institutional shareholder, holding 9.69% of BEAM shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 5.77% of its assets in Beam Therapeutics shares.

BEAM Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBeam Therapeutics95.85%1.42%2.73%
SectorHealthcare Stocks 88.01%8.90%3.09%
IndustryBiotech Stocks 109.70%8.77%-18.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management7.91M9.69%$185.40M
Vanguard group7.90M9.67%$185.11M
Blackrock7.63M9.34%$178.87M
Ark investment management7.07M8.58%$175.29M
Arch venture management5.44M6.66%$127.53M
Fmr4.41M5.40%$103.27M
Sumitomo mitsui trust3.96M4.80%$98.15B
State street3.49M4.27%$81.82M
Mwg management2.27M2.77%$53.11M
Nikko asset management americas2.22M2.72%$52.07M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mwg management2.27M58.01%$53.11M
Arch venture management5.44M47.94%$127.53M
Redmile group1.70M2.41%$39.90M
Yiheng capital management845.50K1.60%$19.81M
Ark investment management7.07M1.46%$175.29M
Casdin capital675.00K1.21%$15.82M
Farallon capital management7.91M0.87%$185.40M
Tang capital management270.00K0.64%$6.33M
Nikko asset management americas2.22M0.60%$52.07M
Bellevue group1.42M0.54%$33.23M

Top Buyers

HolderShares% AssetsChange
Arch venture management5.44M47.94%5.44M
Farallon capital management7.91M0.87%3.40M
First trust advisors lp1.48M0.04%1.48M
Blackrock7.63M0.00%928.75K
Deutsche bank ag\861.99K0.01%801.24K

Top Sellers

HolderShares% AssetsChange
Morgan stanley803.83K0.00%-3.32M
Darwin global management---2.12M
Fmr4.41M0.01%-486.76K
Cormorant asset management, lp---300.00K
Pictet asset management sa9.66K0.00%-292.36K

New Positions

HolderShares% AssetsChangeValue
Arch venture management5.44M47.94%5.44M$127.53M
First trust advisors lp1.48M0.04%1.48M$34.73M
Norges bank410.80K0.00%410.80K$9.63M
Mirae asset global etfs174.18K0.01%174.18K$4.08M
Bank of montreal /can/151.07K0.00%151.07K$3.68M

Sold Out

HolderChange
Assetmark-8.00
Nelson, van denburg & campbell wealth management group-14.00
Advisornet financial-45.00
Piscataqua savings bank-50.00
Macroview investment management-80.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20242251.81%78,990,3511.88%951.08%102-5.56%664.76%
Jun 30, 2024219-6.01%77,530,74310.73%941.15%107-21.90%6231.91%
Mar 31, 202423319.49%70,020,5921.73%901.20%13733.01%47-11.32%
Dec 31, 2023195-2.50%68,827,6552.56%871.13%103-7.21%5326.19%
Sep 30, 2023200-0.99%67,110,0094.58%871.12%11111.00%42-2.33%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite4.78M5.77%535.99K
ARK Innovation ETF4.70M5.68%15.23K
Nikko AM ARK Disruptive Innovation A USD2.47M2.99%33.61K
Vanguard Total Stock Mkt Idx Inv2.31M2.79%3.10K
iShares Russell 2000 ETF2.08M2.51%-315.00
Vanguard Small Cap Index1.90M2.29%23.85K
ARK Genomic Revolution ETF1.76M2.12%-
ARK Genomic Revolution1.75M2.11%-189.12K
BB Biotech AG Ord1.52M1.83%-
Nikko AM ARK Pstv Chg Innovt P JPY Acc1.23M1.48%268.61K

Recent Insider Transactions

DateNameRoleActivityValue
Jan 30, 2025Evans John M. CEOSell$5.46K
Jan 30, 2025Evans John M. CEOSell$797.03K
Jan 02, 2025Bellon Christine Chief Legal OfficerSell$30.63K
Jan 02, 2025Cavanagh Bethany J SVP, Finance and TreasurerSell$27.57K
Nov 06, 2024Ciaramella Giuseppe PresidentSell$1.35M

Insider Transactions Trends

DateBuySell
2033 Q2--
2024 Q4-2
2024 Q3-3
2024 Q2-7
2024 Q1-7

BEAM Ownership FAQ

Who Owns Beam Therapeutics?

Beam Therapeutics shareholders are primarily institutional investors at 95.85%, followed by 1.42% insiders and 2.73% retail investors. The average institutional ownership in Beam Therapeutics's industry, Biotech Stocks , is 109.70%, which Beam Therapeutics falls below.

Who owns the most shares of Beam Therapeutics?

Beam Therapeutics’s largest shareholders are Farallon capital management (7.91M shares, 9.69%), Vanguard group (7.9M shares, 9.67%), and Blackrock (7.63M shares, 9.34%). Together, they hold 28.70% of Beam Therapeutics’s total shares outstanding.

Does Blackrock own Beam Therapeutics?

Yes, BlackRock owns 9.34% of Beam Therapeutics, totaling 7.63M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 178.87M$. In the last quarter, BlackRock increased its holdings by 928.75K shares, a 13.85% change.

Who is Beam Therapeutics’s biggest shareholder by percentage of total assets invested?

Mwg management is Beam Therapeutics’s biggest shareholder by percentage of total assets invested, with 58.01% of its assets in 2.27M Beam Therapeutics shares, valued at 53.11M$.

Who is the top mutual fund holder of Beam Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Beam Therapeutics shares, with 5.77% of its total shares outstanding invested in 4.78M Beam Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools